MedTrace Logo

Clinical Study of CAR-iNKT Cells in the Treatment of Relapsed/Refractory/High-risk B-cell Tumors

NCT04814004 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2021-03-29

No results posted yet for this study

Summary

This study aims to evaluate the safety and feasibility of hCD19.IL15.CAR-iNKT cells in treating patients with relapsed/refractory/high-risk B-cell tumors.

Conditions

Interventions

DRUG

hCD19.IL15.CAR-iNKT

Universal hCD19.IL15.CAR-iNKT cells by a single infusion intravenously will be given in escalating doses.

Sponsors & Collaborators

  • North Jiangsu People's Hospital

    collaborator UNKNOWN

  • The First People's Hospital of Changzhou

    collaborator OTHER

  • Nantong University

    collaborator OTHER

  • First Affiliated Hospital of Zhejiang University

    collaborator OTHER

  • Affiliated Hospital of Jiangsu University

    collaborator OTHER

  • Huai 'an First People's Hospital

    collaborator UNKNOWN

  • Kai Lin Xu; Jun Nian Zheng

    lead OTHER

Principal Investigators

  • Kailin Xu, Ph.d · The Affiliated Hospital of Xuzhou Medical University

  • Junnian Zheng, Ph.D · Xuzhou Medical University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
5 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-19
Primary Completion
2023-04-01
Completion
2024-04-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04814004 on ClinicalTrials.gov